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ABSTRACT
Halter F, Peskar B, Rainsford KD, Schmassmann A. Cytoproteetoin and healing: two unequal brethren.
lnflammopharmacology. 1997;5:407-414.
The promotion ofthe concept ofcytoprotection has fosteredhopes that the use of co-prescribed mucosal
protective agents wou ldrevolutionize the prevention of NSAID-induced ulcers and supply the basis for
novel ulcer therapy. Prostaglandius do no t ,however, accelerate ulcer healing when applied at doses that
exert an unequivocal cytoprotective activity. At temptshave therefore been made in recent years to create
new less-toxic NSAIDs, such as combined lipoxygcnase/cyclo-oxygenase in~'oitors, N S A I D scoupled to
an N O donor and so-called COX-2 inhibitors. All these preparations do in fact exert a diminished
gastrointestinal toxicity. There ishowever increasing evidence accumulating from studies performed in
and outside our laboratories that in chronic ulcer models their increasedgastrointestinal tolerance is not
necessarily reflectedby non-interference with ulcer healing. It is thus mandatory to distinguish between
cytoprotcctive and healingproperties of drugs interferingwith the cyclo-oxygenase pathway.
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Chronic infection with Helicobacter pylori and non-steroidal anti-inflammatory drugs
(NSAIDs) represent the two most important pathogenic factors in peptic ulcer disease
[1-3]. Since eradication of H. pylori can cure peptic ulcer disease in the majority of H.
pylori-associated peptic ulcers, increasingly more attention is given to prevention and
therapy of NSAID-induced ulcers. This is of particular importance since NSAIDs are
highly liable to produce severe ulcer complications such as massive gastrointestinal
haemorrhage or perforation from complicated peptic ulcers [4,5]. It is now increasingly
recognized that the occurrence of such complications is not restricted to the stomach
and duodenum but can also result from ulcers localized in the small and large bowel
[6]. Chronic administration of NSAIDs produces gastroduodenalmucosal erosions in
35--60% of patients, ulcerations in 10--25%, and severe gastrointestinal haemorrhage or
perforation in < 1% [2,4,5]. In experimental and clinical conditions, indomethacin
delays gastric ulcerhealing [7,8]. Among the mechanisms proposed for delayed healing
are: (a) inhibition of synthesis ofprostaglandins that are important for gastroduodenal
mucosal defence [9-11], (b) inhibition of epithelial cell proliferation in the ulcer margin
that is critical for re-epithelialization of the ulcer crater [7,12,13], (c) inhibition of
angiogenesis that is essential for nutrient supply in the ulcer bed [12] and, (d) inhibition
of proliferation and function of myofibroblasts involved in remodelling and contrac-
tion of the granulation tissue in the ulcer bed [12,14].
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NSAIDs inhibit prostaglandin synthesis by the gastric mucosa and thromboxane
production by platelets so impairing platelet aggregation. Within 90 rain of acute
aspirin ingestion in humans, extensive intramueosal petechial haemorrhage becomes
visible and this is, in part, related to promotion of bleeding from the antiplatelet
actions of aspirin. With longer term ingestion, the number of erosions may diminish,
possibly by a process of adaptation [15]. However, erosions, petechiae and superficial
ulcers are quite common in patients on long-term maintenance treatment with
NSAIDs. Moreover, it is not established why a small proportion of patients develop
chronic ulcers yet others exhibit little or no mucosal damage.
The promotion of the concept of cytoprotection by the late Andr6 Robert [9] had
fostered hopes that the use of co-prescribed mucosal protective agents w o u l d
revolutionized the prevention of NSAID induced ulcers and supply the basis for novel
ulcer therapy. The hopes were, however, only partially fulfilled. Thus, endoscopic
studies haveshown that the prostaglandin analogue misoprostol reduces the incidence
of gastric and duodenal ulcers and the admission rate to hospital with ulcer
complications [11]. Prostaglandins did not, however, revolutionize peptic ulcer
therapy; they only exert modest ulcer healing a t high acid-inhibitory doses [16].
Moreover, gastric biopsy lesions do not heal faster when diclofenac is combined with
misoprostol treatment [17]. Profound acid suppression by high-dose proton pump
inhibitors (PPIs) is, however, highly effective in the treatment of NSAID-induced
gastroduodenal ulcerations both in man and experimental models [7,12,18,19]. The
advantage of the PPIs against prostanoids in ulcer prevention therapy is better
tolerance, whereas their limitation is based on the highercosts and possible undesirable
side-effect of long-term anacidity (e.g. promotion of bacterial overgrowth with its
theoretical carcinogenic potential).
N O V E L NSAIDs AND T H E I R TOXICITY IN ACUTE MODELS
Numerous strategies have been used in recent years to develop new anti-inflammatory
and analgesic drugs that spare the gastrointestinal tract.
Several groups are attempting to develop NSAIDs that predominantly inhibit effects
on lipoxygenase or other particularly non-ulcerogenic pathways of lipid metabolism
and/or which have antioxidant activity. Tebufelone, one of these compounds, display-
ing both lipoxygenase and cyclo-oxgenase activity, has been shown to be gastroprotec-
tive in various models of NSAID-induced injury [20,21].
Another strategy for developing gastrointestinal-sparing NSAIDs is the coupling of
a nitric oxide-releasing moiety to a standard NSAID [22-29]. The rationale behind this
strategy is that the nitric oxide (NO) released from these derivatives will exert
beneficial effects on the mucosa by maintaining gastrointestinal b l o o d flow and
inhibiting adherence and activation of white blood cells with the gastrointestinal
mucosa [22,23]. These promises are clearly fulfilled with regard to better acute
tolerance and the results of one study suggest that experimental ulcer healing is not
compromisedby this treatment modality [23].
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The most recent strategy is based on the recognition that cyclo-oxygenase (COX),
the rate-limiting enzyme o f prostaglandin (PG) synthesis exists in two forms, a
constitutive COX-1 and an inducible COX-2, whereby the la t te r is activated in
inflammatory exudates in rheumatic disease. By contrast PGs produced in normal
gastric tissue are derived from COX-1 [30]. COX-2 inhibitors should thus theoretically
be free o f gastrointestinal toxicity. The specific COX-2 inhibitor, L-745,337, has indeed
been shown to produce minimal toxicity in acute gastric models, including in studies
from our own laboratories [31-33].
Hopes have been nourished for all the three groups o f the above discussed novel
NSAIDs, that these compounds will not compromise u lcer healing and possibly even
accelerate u lcer healing.
STUDIES ON H E A L I N G OF C H R O N I C EXPERIMENTAL U L C E R S
We have performed a detailed analysis aimed at investigating how each o f the three
above-mentioned NSAIDs would interfere with the complex healing kinetics o f gastric
ulcers. The studies were performed in a cryo-ulcer model in the rat which allows a very
precise analysis o f healing through repeat endoscopy with exact measurements o f the
residual u lce r size [12]. In summary female Wistar rats with an initial body weight o f
200-220 g were used. To permit regular endoscopic control o f the healing process, a
fistula cannula o f the type generally used for gastric secretion studies (inner diameter 8
mm) was implanted in the forestomach under ether anaesthesia, three weeks pr ior to
the onset o f the study. Af t e r a 3-week recovery period, laparotomy was again
performed in o rde r to induce an experimental ulcer with a cryoprobe (outer diameter
6.5 mm), which was placed on the gastric mucosa on the posterior wall o f the central
part o f the corpus (duration 45 s) to generate standardized ulcers. The size o f the u lcer
was measured every 2-3 days using a video-endoscopic system. An arthroscope with a
30° oblique-viewing optical system (Stortz, Tuttlingen, FRG) was used in conjunction
with an Olympus videocamera. Fo r the examination, the rats were immobilized in
Bollmann cages. Endoscopy required neither anaesthesia n o r pr ior fasting. The
stomach was irrigated via the fistula cannula to remove food particles. To record the
size o f the ulcer, a piece o f calibrated paper (diameter 4 mm) was introduced via the
fistula cannula and positioned next to the ulcer with the tip o f the endoscope In two
series o f experiments, healing o f cryo-ulcers was sequentially studied over a 15-day
treatment period. The objectives o f the first study were to analyse the effects o f
tebufelone and nitrofenac on ulcer healing in the above described rat u lce r model.
The doses oftebufelone were either 1 o r 10 mg/kg ig twice daily, and that for nitrofenac
3.75 mg/kg, ig twice daily. The comparators were placebo, omeprazole 40 ~tmol/kg sc,
once daily, indomethacin 0.5 mg/kg sc, twice daily, diclofenac 2.5 mg/kg ig, twice
daily, indomethacin 0.5 mg/kg sc twice daily + omeprazole 40 lunol/kg sc once daily.
Rats were randomly treated with the above-mentioned medications for 15 days.
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Figure 1. Ulcer healing curve assessed by video endoscopy. (A) The data indicate mean
percentage residualulcer size + SEM over the observation time points. (B) Residualulcer size
on day 15 as a percentage of the initial ulcer size on day 1. p < 0.05 vs. placebo(ANOVA)
The objective o f the second study was to examine the effects on ulcer healing o f the
COX-2 inhibitor, L-745,337. The doses used were 0.5 mg/kg, 2 mg/kg and 5 mg/kg,
twice daily ig for 15 days. The same control treatments were applied as in the
tebufelone/nitrofenac study.
As shown in Figures 1 and 2, all the three novel NSAIDs similarly delayed healing o f
the cryo-ulcers by a pattern o f interference with the healing kinetics similar to that o f
indomethacin or diclofenac. By contrast, healing was accelerated during omeprazole
monotherapy. The healing delay induced by the NSAIDs became substantial only in
the second treatment week, while omeprazole accelerated healing predominantly in the
first week. Concomitant treatment with omeprazole reversed the healing kinetics under
NSAID treatment to the placebo values, thus still partly interfering with the speed-
promoting effect which omeprazole exerts on healing.
In the second study, the dose-response relationship for the inhibition o f gastric ulcer
healing rates from days 8-15 was compared between indomethacin, diclofenac and L-
745,337 (n =26) The IDso values were 0.4 mg/kg, 0.8 mg/kg, and 1.7 mg/kg
respectively (Figure 3).
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Figure 2. Ulcer healing curve assessed by video endoscopy: (A) The data indicate mean
percentage residualulcer size-I-SEM over the observation time points. (B) Residualulcer size
on day 15 as a percentage ofthe initial ulcer size on day 1. p < 0.05 vs. placebo(ANOVA)
PATHOPHYSIOLOGICAL BACKGROUND FOR I N T E R F E R E N C E OF
NOVEL NSAIDs WITH U L C E R H E A L I N G
In search o f reasons for the interferenceon healing o f the COX-2 inhibitor, L-745,337,
microvessel density was quantified in the granulation tissue below the ulcer c ra te rand
compared with the known suppressive effects o f conventional NSAIDs , such as
indomethacin and diclofenac, on angiogenesis [12]. Fo r all three compounds, a dose-
dependent inhibition o f angiogenesis was verified. The IDso values were 0.5 mg/kg for
indomethacin, 1.0 mg/kg fo r diclofenac and 2.1 mg/kg for L-745,337. COX-2
immunoreactivity was not detected in glandular cells but in endothelial cells and many
macrophages and fibroblasts in the submucosa and the granulation tissue involved in
the healing process during days 3-15.
The result o f our studies can be regarded as a further confirmation that increased
tolerance o f the gastric mucosa for those novel NSAIDs that are better tolerated by the
intact gastric mucosa does not guarantee non-interference with u lcer healing. During
ulcer healing angiogenesis is a rate-limiting factor and the observation made in our
study that L-745,337 interferes with angiogenesis in a similar way to conventional
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Figure 3. Dose-response curves for the inhibition of gastric ulcer rate from days 8-15 by
indomethacin (A), diclofenac (D), and L-745,337 (11) in a chronic cryo-ulcer model. IDs0
values for the doses administered twice daily are 0.4 mg/kg, 0.8 mg/kg, and 1.7 mg/kg for
indomethacin (so), diclofenac (ig), and L-745,337 (ig), respectively. The difference between
indomethacin and L-745,337 is significant (p<0.001); in contrast, the difference between
diclofenac ajad L-745,337 is not significant
NSAIDs explains at least in part the u lcer healing delay.There is increasing evidence
from recent studies that COX-2, albeit largely absent in healthy mucosa is abundantly
expressed a t the edge o f healing ulcers [34-36]. This is not really surprising since the
COX-2 is abundant in inflammation such as in arthritic exudates. A t the u lcer edge
COX-2 expression has been verified by immunohistochemical techniques in micro-
vessels [36,37] and macrophages. This has recently been confirmed with molecular
biology techniques [37] by a Japanese group which has also confirmed in a mouse
model that healing o f acetic acid ulcers is delayed by a COX-2 inhibitor.
There is also a n explanation for the conflicting results obtained with diclofenac
coupled with an NO donor. In their study, Elliot et al. [23] supplied some data
suggesting that this compound is not delaying healing o f ulcers in the rat acetic acid
model, but even slightly accerating ulcer cicatrization. Their study has, however, the
limitation that NSAID medication was limited to the first week, in which all NSAIDs
interfere only minimally with ulcer healing, as clearly outlined in our u lcer model,
which allows complete analysis o f the healing kinetics.
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CONCLUSION
Our studies have dearly outlined that for prediction of gastric tolerance a clear
distinction is necessary between cytoprotective and healing properties of drugs
interfering with the cylco-oxygenase and lipoxygenase pathway of prostaglandin
generation. These studies do not, however, exclude the possibility that these novel
N S A I D s offer a therapeutic advantage due to better tolerance during short-term
administration. Further studies are, however, necessary to determine whether this
optimized gastrointestinal safety profile is maintained during long-term application.
Caution appears to b e particularly warranted against their uncritical application in
patients suffering from pepticulcer disease.
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